Abstract:Background Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease with a poor prognosis in which synovitis induces progressive destruction of bones and joints, which leads to marked impairment of the activities of daily living.More timely and effective therapy for rheumatoid arthritis has contributed to increasing rates of clinical remission. However, progression of structural damage may still occur in patients who have satisfied remission criteria (1,2).Most RA patients who satisfied the remission criteria with normal findings on clinical and laboratory studies had imaging-detected synovitis may explain the observed discrepancy between disease activity and outcome in RA (3). Objectives To evaluate theeffects of double filtration plasmapheresis (DFPP) in combination with Leflunomide and methotrexate on magnetic resonance imaging (MRI)-detected inflammatory changes (synovitis and bone marrow edema) in early rheumatoid arthritis (RA) patients with high disease activity. Methods Sixty RA patients with high active disease of 6 months to3 years’ duration were randomized to DFPP group and no-DFPP group. All patients received leflunomide10mg, two times daily, plus methotrexate15mg orally once weekly. DFPP was performed in the DFPP group once 1-2 weeks for 3 sessions. The primary end point was the improvement in MRI-detected synovitis from baseline over 6 months. Secondary end point variables included Clinical remission in DAS28 and ACR20, ACR50, ACR70 and ACR90 responses for 6 consecutive months. Results The study achieved a significant reduction in synovitis compared with baseline, witha reduction of 7 in the median synovitis score from baseline to month 6in the DFPP group compared with 0 in the median synovitis score from baseline to month 6for the no-DFPP group (P<0.001). Synovitis scores in 48.39% (15/31)of the Patients in the DFPP group were 0 at month 6.Bone edema scores in 32.26% (10/31) of the Patients in the DFPP group were 0 at month 6. ACR20, ACR50, ACR70 and ACR90 responses for 6 consecutive months had been achieved in 100% of patients in the DFPP group, compared with 37.93%, 20.69%, 10.34%, 0% respectively, of patients in the no-DFPP group (P<0.001). DAS28 remissionfor 6 consecutive months was achieved in 100% of patients in the DFPP group, compared with 6.90%of patients in the no-DFPP group (P<0.001). Conclusions The combination of DFPP and DMARDs is superior to DMARDs alone for reducing MRI-detected signs of synovitis and bone edema in patients with early high active rheumatoid arthritis. The DFPP therapy enables a rapid and more complete suppression of inflammation in patients withearly high active rheumatoid arthritis. Nearly half of the patients (48.39%) who had received DFPP therapy achieved both clinical remission and imaging remission,a true remission. References Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis.J Rheumatol 2001,28:881-886. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of Radiologic Damage in Patients With Rheumatoid Arthritis in Clinical Remission. Arthritis Rheum 2004; 50:36-42. Brown AK, Conaghan PG, Karim Z, Quinn M A, Ikeda K, Peterfy CG, et al. An Explanation for the Apparent Dissociation Between Clinical Remission and Continued Structural Deterioration in Rheumatoid Arthritis. Arthritis & Rheumatism 2008,58: 2958-2967. Disclosure of Interest None Declared

Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis

THU0156 Response of Ra on MRI-detected Synovitis to Double Filtration Plasmapheresis

Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis

Value of Magnetic Resonance T1 Mapping in Evaluating the Early Response to Treatment for Rheumatoid Arthritis

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis

Prediction of radiographic progression during a treat-to-target strategy by the sequential application of MRI-proven bone marrow oedema and power-Doppler grade ≥2 articular synovitis in rheumatoid arthritis: Retrospective observational study

Early Prediction of Rheumatoid Arthritis by Magnetic Resonance Imaging in the Absence of Anti-Cyclic Citrullinated Peptide Antibodies and Radiographic Erosions in Undifferentiated Inflammatory Arthritis Patients: A Prospective Study

Comparison of hand magnetic resonance imaging in patients with rheumatoid arthritis treated by recombinant human tumor necrosis factor-Fc plus methotrexate

Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials

Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial

Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial

Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start

Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM

Continuously Elevated Serum Matrix Metalloproteinase-3 for 3 ~ 6 Months Predict One-Year Radiographic Progression in Rheumatoid Arthritis: a Prospective Cohort Study

E073 The use of magnetic resonance imaging to assess disease activity in axial spondyloarthritis- data from a tertiary rheumatology centre

Six-month prospective trial in early and long-standing rheumatoid arthritis: evaluating disease activity in the wrist through sequential synovial histopathological analysis, RAMRIS magnetic resonance score and EULAR-OMERACT ultrasound score

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Prognostic modeling in early rheumatoid arthritis: reconsidering the predictive role of disease activity scores